Strategies toward single-donor islets of Langerhans transplantation
- 1 December 2011
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Organ Transplantation
- Vol. 16 (6), 627-631
- https://doi.org/10.1097/mot.0b013e32834cfb84
Abstract
Purpose of review The current review addresses a critical need in clinical islet transplantation, namely the routine transition from the requirement of two to four donors down to one donor per recipient. The ability to achieve single-donor islet transplantation will provide many more islet grafts for treatment of an ever-expanding patient base with type 1 diabetes (T1DM) with poor glycemic control. Avoiding exposure of recipients to multiple different donor human leukocyte associated (HLA) antigens is critical if risk of donor sensitization is to be avoided. This point is important as further islet or pancreas transplants in the remote future or the potential future need for a solid organ kidney transplant may become prohibitive if the recipient is sensitized. Recent findings This review addresses systematically all areas that contribute to the success or failure of single-donor islet engraftment, beginning with donor-related factors, optimizing islet isolation and culture conditions, and describes a series of strategies in the treatment of the recipient to prevent inflammation, apoptosis, islet thrombosis, and improve metabolic functional outcome, all of which will lead to improved single-donor engraftment success. Summary If single-donor islet transplantation can be achieved routinely, therapy will become more widely available, more accepted by the transplant community (currently pancreas transplantation requires only a single donor), and this situation will have a major impact overall as an effective treatment option in T1DM.Keywords
This publication has 28 references indexed in Scilit:
- Islet Transplantation in Type 1 Diabetic Patients Using Calcineurin Inhibitor-Free Immunosuppressive Protocols Based on T-Cell Adhesion or Costimulation BlockadeTransplantation, 2010
- Insulin-Heparin Infusions Peritransplant Substantially Improve Single-Donor Clinical Islet Transplant SuccessTransplantation, 2010
- Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in cultureTransplant International, 2010
- Long-Term Metabolic and Hormonal Effects of Exenatide on Islet Transplant Recipients with Allograft DysfunctionCell Transplantation, 2009
- Low Molecular Weight Dextran Sulfate Is Well Tolerated in Humans and Increases Endogenous Expression of Islet Protective Hepatocyte Growth FactorTransplantation, 2008
- Combination Therapy with Glucagon-Like Peptide-1 and Gastrin Induces β-Cell Neogenesis from Pancreatic Duct Cells in Human Islets Transplanted in Immunodeficient Diabetic MiceCell Transplantation, 2008
- A New Method for Incorporating Functional Heparin onto the Surface of Islets of LangerhansTissue Engineering, Part C: Methods, 2008
- Recovery from diabetes in mice by β cell regenerationJCI Insight, 2007
- Human Islet Oxygen Consumption Rate and DNA Measurements Predict Diabetes Reversal in Nude MiceAmerican Journal of Transplantation, 2007
- Repurification: Rescue Rather Than Routine RemedyAmerican Journal of Transplantation, 2005